Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Gu, SS; Zhang, WB; Wang, XQ; Jiang, P; Traugh, N; Li, ZY; Meyer, C; Stewig, B; Xie, YT; Bu, X; Manos, MP; Font-Tello, A; Gjini, E; Lako, A; Lim, K; Conway, J; Tewari, AK; Zeng, ZX; Das Sahu, A; Tokheim, C; Weirather, JL; Fu, JX; Zhang, Y; Kroger, B; Liang, JH; Cejas, P; Freeman, GJ; Rodig, S; Long, HW; Gewurz, BE; Hodi, FS; Brown, M; Liu, XS

Liu, XS (corresponding author), Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, 44 Binney St,LW641, Boston, MA 02115 USA.; Brown, M (corresponding author), SM1022D,450 Brookline Ave, Boston, MA 02215 USA.

CANCER DISCOVERY, 2021; 11 (6): 1524

Abstract

Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many patients with impaired MHC-I expression remain refractory. Here, we......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索